📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Synimmune

1.1 - Company Overview

Synimmune Logo

Synimmune

Headquarter: Germany
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of innovative mono- and bispecific anti-tumor antibodies for treating life-threatening diseases, focusing on orphan hematopoietic malignancies; lead product candidate is the antibody FLYSYN.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Synimmune

IONIQ Sciences Logo

IONIQ Sciences

HQ: United States Website
  • Description: Provider of solutions for early detection of multiple cancers to improve survivability and reduce healthcare costs.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full IONIQ Sciences company profile →
MaxiVAX Logo

MaxiVAX

HQ: Switzerland Website
  • Description: Provider of clinical-stage cancer immunotherapies and cell-encapsulation delivery platforms, including MVX-ONCO-1 for recurrent/metastatic head and neck squamous carcinoma, Encapsulated Cell Technology for sustained, controlled protein delivery (e.g., low-dose anti-CTLA-4 in a colorectal cancer model), and MVX-ONCO-2, a second-generation personalized immunotherapy for advanced solid tumors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full MaxiVAX company profile →
Valerio Therapeutics Logo

Valerio Therapeutics

HQ: United States Website
  • Description: Provider of clinical-stage oncology therapeutics leveraging the platON chemistry platform to generate DNA-decoy compounds targeting intracellular DNA-binding proteins for tumors and inflammatory diseases; develops AsiDNA and VIO-01 to disrupt DNA repair and activate the STING pathway, and Belinostat/Beleodaq, a histone deacetylase inhibitor for hematological and solid tumors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Valerio Therapeutics company profile →
Vor Bio Logo

Vor Bio

HQ: United States Website
  • Description: Provider of immuno-oncology therapies for AML, including VOR33, a gene-edited hematopoietic stem cell therapy lacking CD33 to shield healthy blood cells from targeted therapies, and VCAR33ALLO, an allogeneic anti-CD33 CAR-T for relapsed or refractory post-transplant AML. Runs clinical trials (VBP101, VBP301) and collaborates with blood cancer advocacy groups to support the AML patient community.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vor Bio company profile →
Epigenomics Logo

Epigenomics

HQ: Germany Website
  • Description: Provider of molecular diagnostics, developing and commercializing in vitro cancer diagnostic tests to detect cancer at early stages using body fluids such as blood plasma; offerings include Epi proColon, a blood test for colorectal cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Epigenomics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Synimmune

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Synimmune

2.2 - Growth funds investing in similar companies to Synimmune

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Synimmune

4.2 - Public trading comparable groups for Synimmune

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Synimmune

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Synimmune

What does Synimmune do?

Synimmune is a provider of innovative mono- and bispecific anti-tumor antibodies for treating life-threatening diseases, focusing on orphan hematopoietic malignancies; lead product candidate is the antibody FLYSYN.

Who are Synimmune's competitors?

Synimmune's competitors and similar companies include IONIQ Sciences, MaxiVAX, Valerio Therapeutics, Vor Bio, and Epigenomics.

Where is Synimmune headquartered?

Synimmune is headquartered in Germany.

How many employees does Synimmune have?

Synimmune has 1,000 employees 🔒.

When was Synimmune founded?

Synimmune was founded in 2010 🔒.

What sector and industry vertical is Synimmune in?

Synimmune is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Synimmune

Who are the top strategic acquirers in Synimmune's sector and industry

Top strategic M&A buyers and acquirers in Synimmune's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Synimmune?

Top strategic M&A buyers groups and sectors for Synimmune include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Synimmune's sector and industry vertical

Which are the top PE firms investing in Synimmune's sector and industry vertical?

Top PE firms investing in Synimmune's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Synimmune's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Synimmune's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Synimmune's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Synimmune include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Synimmune's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Synimmune?

The key public trading comparables and valuation benchmarks for Synimmune include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Synimmune for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Synimmune with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Synimmune's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Synimmune with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Synimmune's' sector and industry vertical?

Access recent funding rounds and capital raises in Synimmune's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Synimmune